University of East Anglia Featured PhD Programmes
Xi’an Jiaotong-Liverpool University Featured PhD Programmes
Lancaster University Featured PhD Programmes
United Kingdom
Manchester×
10 miles

Pharmacology / Toxicology PhD Projects, Programs & Scholarships in Manchester

We have 20 Pharmacology / Toxicology PhD Projects, Programs & Scholarships in Manchester

  • Pharmacology / Toxicology×
  • United Kingdom×
  • Manchester×
  • clear all
Order by 
Showing 1 to 15 of 20
  Characterising B cells in Rheumatoid Arthritis: Their role in susceptibility, pathogenesis, and treatment response
  Dr S Viatte, Dr D Plant, Dr Q-J Meng, Prof A Barton
Applications accepted all year round

Funding Type

PhD Type

Note. Dr D Plant is the main supervisor for this project. Background. Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that primarily affects the joints.
  Understanding differential responses to retinoid treatments in human health and disease: a precision medicine approach
  Prof R Watson, Dr A Langton
Applications accepted all year round

Funding Type

PhD Type

Retinoids, such as all-trans retinoic acid (t-RA), are endogenous signalling molecules derived from vitamin A that influence a variety of cellular processes through mediation of transcription events in the cell nucleus.
  Development of a three dimensional in vitro model of the human cornea to dissect the inflammatory events associated with sight-threatening ocular pathogens
  Dr C Dobson, Dr C Maldonado-Codina, Prof P Morgan
Applications accepted all year round

Funding Type

PhD Type

The presence of microbes at the corneal surface may trigger low grade discomfort through to acute eye infection and permanent loss of vision.
  In vitro assessment of drug sequestration into lysosomes and in silico prediction of implications for drug disposition and therapeutic efficacy
  Dr A Galetin, Dr D Hallifax
Applications accepted all year round

Funding Type

PhD Type

Intracellular concentration of a drug is an important determinant of its efficacy, toxicity, and potential drug-drug interactions [1].
  Accurate energy evaluation of receptor-ligand interaction
  Prof P Popelier, Dr S De Visser
Applications accepted all year round

Funding Type

PhD Type

Drug design routinely uses existing computational methods to evaluate the interaction energy between receptor (protein) and ligand (drug) in molecular docking.
  Cutting off the fuel supply to calcium pumps in pancreatic cancer: a novel therapeutic strategy
  Dr J Bruce, Prof K Williams, Dr A P Gilmore
Applications accepted all year round

Funding Type

PhD Type

Background and Rationale. Pancreatic ductal adenocarcinoma (PDAC) has the poorest survival and limited treatment options. Therefore, the search for novel therapeutic targets and drugs designed to selectively kill PDAC cells must remain a central research strategy.
  Protease-resistant antimicrobial peptides to target bacterial and fungal pathogens
  Dr J Bella, Dr L Tabernero
Applications accepted all year round

Funding Type

PhD Type

Antimicrobial resistance is quickly becoming a serious global health problem. The emergence of multidrug-resistant microbial strains combined with the drying up of the antibiotic pipeline in the pharmaceutical industry has significantly worsened the situation in recent years.
  Is there a switch between prostamides and prostaglandins in women with dysmenorrhoea and heavy menstrual bleeding?
  Prof K Marshall, Dr D Fischer, Prof A Nicolaou
Applications accepted all year round

Funding Type

PhD Type

Dysmenorrhoea, painful menstrual cramps, and heavy menstrual bleeding are common debilitating symptoms in women with or without an underlying pelvic pathology.
  Structure based design of novel warheads for use in peptide-drug conjugates
  Dr S Butterworth, Dr A Tirella, Dr D Wiseman
Applications accepted all year round

Funding Type

PhD Type

Chronic Myelomonocytic Leukaemia (CMML) is an orphan disease defined by myeloid dysplasia, myeloproliferation and a malignant expansion of classical monocytes.
  Targeting ERK5 to enhance the DNA damage response to radiotherapy and chemotherapy
  Dr K Finegan, Dr C Demonacos
Applications accepted all year round

Funding Type

PhD Type

ERK5 is a signalling protein that enables cells to transduce extracellular signals into responses. It is expressed in all tissues and is up-regulated in tumours.
  Fostering development of ‘smart’, responsive therapeutics against cancer-related microRNAs.
  Dr E Bichenkova, Prof D Clarke, Dr H Aojula
Applications accepted all year round

Funding Type

PhD Type

Short functional non-coding microRNAs are implicated in many types of cancer, and thus can be used as biological targets for development of more selective and powerful anticancer therapies.
  Proteomics to determine how defects in membrane trafficking within the secretory pathway cause human disease
  Prof M Lowe, Prof V Allan
Applications accepted all year round

Funding Type

PhD Type

Work in the Lowe laboratory is aimed at deciphering the molecular mechanisms that control membrane trafficking within cells. A major focus of our work is the trafficking of proteins to and through the Golgi apparatus, which lies at the heart of the secretory pathway.
  How do phosphodiesterases contribute to the pathophysiology of heart failure?
  Prof A Trafford, Dr K Dibb
Applications accepted all year round

Funding Type

PhD Type

Heart failure (HF) remains a major cause of death with worse 5-year survival than all forms of cancer combined. This project seeks to understand the mechanisms that underlie two important contributing factors to death in HF patients; i) contractile failure and, ii) the increased propensity for arrhythmias.
  Exploring the influence of proteogenomics in patients receiving biologic drugs for treatment of psoriatic arthritis
  Prof A Barton, Dr James Bluett, Dr N Nair
Applications accepted all year round

Funding Type

PhD Type

Background. Psoriatic arthritis (PsA) is an inflammatory arthritis, associated with the chronic skin condition psoriasis, which causes joint inflammation.
  Investigating the link between amyloid-β oligomers, neuroinflammation and cognitive deficits in preclinical models for Alzheimer’s Disease
  Dr M Harte, Prof J Neill
Applications accepted all year round

Funding Type

PhD Type

Currently four out of the five pharmacological treatments used for Alzheimer’s disease (AD) are acetylcholinesterase inhibitors aimed at boosting the amount of acetylcholine in the brain, with the fifth being an N-methyl-D-aspartate (NMDA) receptor antagonist.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2020
All rights reserved.